Jonathan Barratt
Overview
Explore the profile of Jonathan Barratt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
208
Citations
5706
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Heerspink H, Jardine M, Kohan D, Lafayette R, Levin A, Liew A, et al.
N Engl J Med
. 2024 Oct;
392(6):544-554.
PMID: 39460694
Background: Patients with IgA nephropathy and severe proteinuria have a high lifetime risk of kidney failure. The efficacy and safety of the selective endothelin type A receptor antagonist atrasentan in...
12.
Lafayette R, Tumlin J, Fenoglio R, Kaufeld J, Perez Valdivia M, Wu M, et al.
J Am Soc Nephrol
. 2024 Oct;
PMID: 39455063
No abstract available.
13.
Perkovic V, Barratt J, Rovin B, Kashihara N, Maes B, Zhang H, et al.
N Engl J Med
. 2024 Oct;
392(6):531-543.
PMID: 39453772
Background: The alternative complement pathway plays a key role in the pathogenesis of IgA nephropathy. Iptacopan specifically binds to factor B and inhibits the alternative pathway. Methods: In this phase...
14.
Selvaskandan H, Barratt J
Kidney Int
. 2024 Sep;
106(6):1008-1011.
PMID: 39332814
No abstract available.
15.
Vivarelli M, Samuel S, Coppo R, Barratt J, Bonilla-Felix M, Haffner D, et al.
Pediatr Nephrol
. 2024 Sep;
40(2):533-569.
PMID: 39331079
IgA nephropathy and IgA vasculitis with nephritis, albeit rare, represent two relatively frequent glomerular conditions in childhood. Compared to adults, pediatric IgA nephropathy has a more acute presentation, most frequently...
16.
Barratt J
Nephrology (Carlton)
. 2024 Sep;
29 Suppl 2:34-36.
PMID: 39327765
IgA nephropathy is a mucosally driven disease and new therapeutic approaches are specifically targeting the mucosal production of IgA in the hope that this will lead to a reduction in...
17.
Selvaskandan H, Barratt J
Kidney360
. 2024 Sep;
5(9):1229-1231.
PMID: 39325588
No abstract available.
18.
Cheung C, Alexander S, Reich H, Selvaskandan H, Zhang H, Barratt J
Nat Rev Nephrol
. 2024 Sep;
21(1):9-23.
PMID: 39232245
IgA nephropathy (IgAN) is a common form of primary glomerulonephritis and represents an important cause of chronic kidney disease globally, with observational studies indicating that most patients are at risk...
19.
Barratt J, Lafayette R, Floege J
Front Med (Lausanne)
. 2024 Aug;
11:1461879.
PMID: 39211339
Immunoglobulin A nephropathy (IgAN) often has a poor outcome, with many patients reaching kidney failure within their lifetime. Therefore, the primary goal for the treatment of IgAN should be to...
20.
Cheung C, Barratt J, Lafayette R, Liew A, Suzuki Y, Tesar V, et al.
Kidney Int
. 2024 Aug;
106(5):806-818.
PMID: 39182759
A proliferation-inducing ligand (APRIL) is a key member of the tumor necrosis factor superfamily of cytokines and plays a central role in B-cell survival, proliferation, and Ig class switching. Recently,...